Dr. Jing Dong of Junke Zhengyuan Invites You to the 2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit

Seizing the historic opportunities presented by the new wave of technological revolution and industrial transformation, Zhongguancun Life Science Park, as a key pillar of Beijing’s “Three Cities and One District” main platform for building an international science and technology innovation center, has invested in and attracted numerous biotechnology innovation platforms, thereby creating agglomeration advantages across the upstream and downstream segments of the industrial chain.On March 24, 2023, Zhongguancun Life Science Park Co., Ltd. joined forces with multiple technology platforms to co-host the “2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit.”, focusing on core themes such as “AI-enabled new drug discovery, breakthroughs in undruggable targets, evaluation of biopharmaceuticals, and preservation and utilization of clinical biospecimens,” this initiative brings together industry leaders, investment experts, and leading or innovative entrepreneurs to integrate the entire chain of industry, academia, research, and application, thereby promoting the development of a multi-level, broad-spectrum, functional, and open support system for novel innovation technology platforms.

Dr. Dong Jing, Executive Director of Junke Zhengyuan, Vice Chairman of the Committee on Pharmaceutical Bioanalysis of the Chinese Association for Medical and Biological Sciences, and Head of the Pharmacokinetics Platform at the National Engineering Research Center for Protein DrugsConfirmed attendance at the Main Forum Roundtable of the 2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit, and delivered related presentations.

Personal Profile

Dr. Jing Dong earned her bachelor’s degree in Biology from Wuhan University, and obtained her master’s and doctoral degrees from McGill University in Canada. With over 25 years of professional experience across North America, Europe, and China, she served as Director of DMPK (Drug Metabolism and Pharmacokinetics) for GSK China R&D and Head of Bioanalysis for the Asia-Pacific region from 2009 to 2018, accumulating extensive expertise in drug metabolism and pharmacokinetics as well as bioanalysis of both small and large molecules. In February 2018, Dr. Dong joined Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. As a founding member of the Chinese Bioanalysis Forum, she currently serves as Vice Chair of the Bioanalysis Professional Committee under the China Pharmaceutical Association, Executive Director of Junke Zhengyuan, and concurrently heads the Pharmacokinetics Platform at the National Engineering Research Center for Protein Drugs.

Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd., a bioanalytical CRO with pioneering scientific capabilities and internationally advanced testing platforms, has long provided high-quality preclinical pharmacokinetic/pharmacodynamic evaluation, protein drug characterization, and clinical sample bioanalysis services to pharmaceutical R&D enterprises. To date, the company has delivered over 1,000 high-quality service projects to more than 400 domestic and international pharmaceutical companies, covering over 70% of innovative biological products in China.

2023 Z-Park Life Science Park Technology Platform R&D Innovation Summit

As China’s biopharmaceutical industry and its supporting sectors gradually reach a turning point toward innovation, with steadily enhancing innovative capabilities and continuous breakthroughs in key biotechnologies, what opportunities will emerge for biopharmaceutical innovation?

This forum will bring together the core lineup of participants to discuss the prospects and future of the healthcare industry under the leadership of biotechnology.

2023 Z-Park Life Science Park Technology Platform Industry-Research Innovation Summit: Biotech Drug Evaluation Forum

With continuous breakthroughs in various types of biopharmaceuticals and novel therapies, how to make optimal decisions at key stages during the non-clinical and clinical evaluation of drugs has become a widespread concern.

This forum will introduce various novel evaluation systems for non-clinical and early-phase clinical trials of pharmaceuticals, along with application case studies of biotechnological drug assessments.

Core Issues

1. Nonclinical Safety Evaluation of Small Nucleic Acid Drugs

2. Exploration and Application of Novel Bioanalytical Techniques in Nonclinical Pharmacodynamic Studies

3. Exploration of a Novel Evaluation System for Early-Stage Clinical Trials

4. Key Points and Case Studies on Immunogenicity Evaluation of Different Types of Vaccines

5. Investment Tracks and Logic in Biopharmaceuticals

6. Development of PBMC-Derived CAR-NK Cell Therapeutics

7. Application of the LC-MS/MS Detection Platform in Bioanalysis of ADC Drugs

This summit is organized byUnder the guidance of the Administrative Committee of Zhongguancun Life Science Park, Zhongguancun Life Science Park Company, Zhongguancun Life Science Park Incubator Company, and Changfa Development Company have joined forces with six core biotechnology innovation platforms: the Zhongguancun AI Drug Discovery Platform, the Beijing Clinical Data and Sample Resource Public Service Platform, the Cryo-Electron Microscopy Platform, the High-Resolution Mass Spectrometry Omics Platform, the Biopharmaceutical Evaluation Platform, and the Integrated Biological CRO Service Platform., by focusing on core aspects of pharmaceutical R&D such as basic research, target discovery, pilot-scale development, and drug analysis, we can further unlock the industry's potential, better foster the continuous growth of emerging business models, and promote high-quality development in the field of life sciences and technology.

AsThe First Grand Event Jointly Hosted by Zhongguancun Life Science Park and Its Technical Platforms, this summit is themed with1 Main Forum + 4 Thematic Sub-forumsin a format that further ensures the depth, breadth, cutting-edge nature, and richness of resources. The main forum will serve as a centralized platform for showcasing the insights of industry participants, with numerous industry leaders engaging in aRegarding Multiple Fields of Biotechnology, Including Laboratory Animals and Viral Infections“brainstorming.” The sub-forum focuses on ““High-Quality Development and Sustainable Growth of Biobank Resources,” “AI-Empowered Innovative Drug R&D,” “Breakthroughs in Undruggable Targets,” and “Evaluation of Biologic Drugs”: Four Key DimensionsIn-Depth Analysis of Innovation and High-Quality Development Pathways and Strategies in Biopharmaceutical Technology

CompilationOver 40 distinguished guests, including national academicians, heads of regulatory agencies, leading academics, executives from multinational pharmaceutical companies, directors of Grade A tertiary hospitals, and senior investors, spanning the six major sectors of government, industry, academia, research, healthcare, and investment., bringing together new ideas, new technologies, and new business models, focusing on hot issues in the industry, jointly seeking truth and insights, and conducting comprehensive, high-level, high-quality, and forward-looking sharing and discussions.

Scan the QR code for more conference details and register now.